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No reported disclosures. October 4, 2018: 12:30 PM Background. The collaboration between antimicrobial stewardship program (ASP) and NICU has implemented key strategies including antibiotic restriction, audits and direct feedback, education, standardized guidelines for neonatal sepsis, and discontinuation of vancomycin at 48 hours if cultures are negative for resistant Grampositive cocci (GPC). We aimed to evaluate the use of vancomycin in our NICU after implementing key changes in 2016, and determine further areas of improvement.
Vancomycin Utilization in a Neonatal
Methods. Retrospective chart review was conducted in NICU patients who received vancomycin between January 1, 2017 and December 31, 2017. The use of vancomycin for surgical prophylaxis was excluded. The outcome measures were the use of vancomycin according to the guidelines and its deviations, monitoring of drug levels, renal function, microbiological, and clinical outcomes. Utilization of vancomycin was also evaluated by days of therapy (DOT) per 1,000 patient-days.
Results. There were 336 vancomycin courses administered to 176 infants. Most of vancomycin use (252/336, 75%) was discontinued at 48 hours. Of these, no infants developed invasive Gram-positive infections requiring reinitiating of vancomycin. Among those with continued vancomycin courses, more than half (45/84, 54%) occurred in the absence of evidence of resistant GPC infections. Commonly stated reason for continuation of vancomycin was the infants' severity of illness. Of the total 319 troughs drawn, 24 (7.5%) had subtherapeutic (<5) trough whereas 61 (19%) had supratherapeutic (>15). Acute kidney injury (increase in serum Cr ≥ 1 time baseline) was found in 6 courses (1.8%), in which four courses (67%) received vancomycin for 48 hours or less. Vancomycin utilization in year 2017 was 61.5 per 1,000 patients/day which has decreased compared with those of previous years 2015-2016 (71.7 and 72.3, respectively) .
Conclusion. The majority of vancomycin use was consistent with our existing guidelines. However, most of our use was for 48 hours, questioning the value of empirical vancomycin for suspected sepsis in our NICU. More judicious use of vancomycin could be improved if subsets of high-risk patients could be identified for initiation of empirical vancomycin.
Disclosures. All authors: No reported disclosures. Background. The objective of the study was to measure effectiveness of a voriconazole clinical practice guideline (CPG) in a pediatric hospital. An interdisciplinary team was convened to develop a CPG to standardize initial voriconazole dosing, appropriate use and timing of therapeutic drug monitoring (TDM), and dose modifications based on measured drug concentrations. To operationalize the CPG, pharmacists with advanced training in pharmacokinetics were granted authority to order laboratory evaluations and make dose adjustments.
Assessment of a Pharmacist-Driven Voriconazole Clinical Practice Guideline in a Children's Hospital
Methods. After 6 months, the initial CPG was reviewed and modified to refine TDM recommendations. Adherence to the guideline and ability of the CPG to achieve target voriconazole trough concentrations were assessed before and after the revision. Patients in the analysis included those admitted to a large free-standing children's hospital and receiving voriconazole for confirmed, probable, or presumed fungal infection from April 1, 2015 to December 31, 2016 (25 subjects, median age 10 years).
Results. The study showed that the use of TDM increased following implementation of a CPG from 42% to 100% with improved timing of TDM to reflect concentrations drawn at steady state. Of the patients receiving TDM, achievement of voriconazole concentration in the therapeutic range increased from 70% to 100% with the CPG; however, there was no improvement in the time to reach target concentration. We observed an inability of American Academy of Pediatrics-recommended doses to reach target concentration in 53% of patients, with doses based on pharmacist judgement performing as well as published dosing.
Conclusion. We conclude that a pharmacist-driven voriconazole CPG improved monitoring and achievement of therapeutic concentrations in our children's hospital. Analysis of effectiveness of our voriconazole CPG in conjunction with pharmacist feedback has been essential to improving patient outcomes and informing future guideline modifications.
Disclosures. All authors: No reported disclosures. Background. Upper Respiratory Infections (URI) represent a significant disease burden to children worldwide. Clinicians must rely on clinical acumen and evidence-based medicine to responsibly prescribe antimicrobials to curb the rise of antimicrobial-resistant pathogens. We propose a model to help clinicians predict the odds of hospital transfer upon initial evaluation of pediatric patients presenting with URI in a low to middle income setting.
Developing a Logistic Regression Model to Aid Clinicians Evaluate Outpatients and Predict Odds of Hospital Transfer in a Nicaraguan
Methods. We performed a prospective cohort study of 2,311 children aged 3 months-15 years enrolled in an outpatient government health clinic in Managua, Nicaragua over a 5-year period. Symptoms, examination findings, laboratory studies, diagnoses, and data on antimicrobial use were collected. Primary outcome was hospital transfer. Using forward-selection logistic regression, we constructed a model of the risk factors and examination findings most likely to predict hospital transfer. WHO criteria were used to risk-stratify pneumonia cases. We examined the frequency and type of antimicrobials used. We then applied Hay et al. 's STARWAVe model to examine its utility in our population.
Results. Of the 2,311 children that participated in the cohort between 2011 and 2015, 2,155 children (93%) experienced one or more URI. Those children experienced a total 18,826 URI episodes. 5,383 (28.6%) of URI cases received antibiotics. 332 URI cases were transferred to the hospital, of which 167 (50.3%) were given antibiotics. Age <2 years, male sex, having four or more symptoms, vomiting, poor appetite, diagnosis of "flu-like illness, " wheezing, subcostal retractions, rhonchi and fever were all independently associated with hospital transfer (P < 0.05). STARWAVe had fair predictive value (AUC = 0.6709) but our model had better predictive value (AUC = 0.7011). Ninety percent of all pneumonia cases were properly managed by WHO criteria.
Conclusion. We defined a set of clinical criteria that predict hospital transfer in a low-and middle-income community setting. We also examined the fit of a validated predictive model developed in a high-income setting and found that this model performed reasonably well in our setting. Overall, most pneumonia cases were treated effectively by WHO criteria indicating that local physicians were properly prescribing antimicrobials.
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